| Literature DB >> 29845274 |
Xin Wang1, Kui-Di Liang2, Jun-Ai Zhang1, Gan-Bin Liu2, Zhi Chen3, Chen Chen1, Ze-Gang Zhuang1, Yu-Qing Liu1, Hou-Long Luo1, Rui Xi Li1, Bi-Ying Zheng1, Jun-Fa Xu1.
Abstract
B cell activating factor (BAFF), a member of the tumor necrosis factor family, is a key cytokine for B cell survival, a function that is essential for B cell maturation and memory. The expression levels of BAFF and its potential contribution to B cell maturation remain elusive in patients with tuberculous pleural effusion (TPE). The present study enrolled 40 healthy controls (HC) and 45 TPE patients, and investigated the levels of BAFF in the plasma and pleural effusion. Concomitantly, B cell subsets including naïve B cell (CD19+IgD+CD27‑), unswitched B cell (CD19+IgD+CD27+), switched B cell (CD19+IgD‑CD27+), total memory B cell (CD19+CD27+), plasma B cell (CD19+IgD‑CD38+CD27+) and transitional B cell (CD19+IgDdim CD38+) in peripheral blood mononuclear cells (PBMCs) and pleural fluid mononuclear cells (PFMCs) were assessed using multicolor flow cytometry. Finally, the associations between BAFF and each sub‑group of B cells in TPE patients were analyzed. Compared with HC cases, an increased BAFF level and elevated frequency of switched B cell were observed in the blood and pleural effusion from patients with TPE. The proportions of naïve B cell, plasma B cell and transitional B cell were lower in the PFMCs of TPE patients. Furthermore, a significant correlation was observed between the level of BAFF, and the proportion of switched B cell in the peripheral blood and pleural effusion of TPE patients. These findings indicated that the B cell profile may be different in the pleural effusion, and BAFF may activate switched B cells to enhance the humoral immune responses in patients with TPE. Further studies are required to elucidate the underlying mechanisms and determine the potential immunotherapy of the BAFF‑switched B cell axis.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29845274 DOI: 10.3892/mmr.2018.9073
Source DB: PubMed Journal: Mol Med Rep ISSN: 1791-2997 Impact factor: 2.952